Switch theme
Sign up to access all valuation multiples
Sichuan Kelun Pharmaceutical Co Ltd is a China-based Pharmaceutical company mainly focused on the production and sales of injection products, including products for glucose injection and sodium chloride injection. It manufactures and sells high-volume injections (infusions), small-volume injections (water needles), sterile powder injections (containing powdered and freeze-dried powder). Its products include tablets, capsules, capsules, granules, oral liquids, peritoneal dialysis fluids, raw material medicines, medical packaging materials, medical instruments, and antibiotic intermediates.
2002
n/a
LTM Revenue $3.0B
LTM EBITDA $704M
$8.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Kelun has a last 12-month revenue (LTM) of $3.0B and a last 12-month EBITDA of $704M.
In the most recent fiscal year, Kelun achieved revenue of $3.0B and an EBITDA of $794M.
Kelun expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Kelun valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $3.0B | XXX | $3.0B | XXX | XXX | XXX |
| Gross Profit | $1.6B | XXX | $1.6B | XXX | XXX | XXX |
| Gross Margin | 51% | XXX | 52% | XXX | XXX | XXX |
| EBITDA | $704M | XXX | $794M | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | 26% | XXX | XXX | XXX |
| EBIT | $571M | XXX | $606M | XXX | XXX | XXX |
| EBIT Margin | 19% | XXX | 20% | XXX | XXX | XXX |
| Net Profit | $410M | XXX | $407M | XXX | XXX | XXX |
| Net Margin | 13% | XXX | 13% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Kelun's stock price is CNY 39 (or $5).
Kelun has current market cap of CNY 61.6B (or $8.6B), and EV of CNY 59.9B (or $8.3B).
See Kelun trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $8.3B | $8.6B | XXX | XXX | XXX | XXX | $0.26 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Kelun has market cap of $8.6B and EV of $8.3B.
Kelun's trades at 2.7x EV/Revenue multiple, and 10.5x EV/EBITDA.
Equity research analysts estimate Kelun's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Kelun has a P/E ratio of 20.8x.
See valuation multiples for Kelun and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $8.6B | XXX | $8.6B | XXX | XXX | XXX |
| EV (current) | $8.3B | XXX | $8.3B | XXX | XXX | XXX |
| EV/Revenue | 2.7x | XXX | 2.7x | XXX | XXX | XXX |
| EV/EBITDA | 11.8x | XXX | 10.5x | XXX | XXX | XXX |
| EV/EBIT | 14.6x | XXX | 13.7x | XXX | XXX | XXX |
| EV/Gross Profit | 5.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | 20.8x | XXX | 21.0x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 21.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialKelun's last 12 month revenue growth is 4%
Kelun's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Kelun's rule of 40 is 28% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Kelun's rule of X is 33% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Kelun and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 4% | XXX | 5% | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | 26% | XXX | XXX | XXX |
| EBITDA Growth | -2% | XXX | -4% | XXX | XXX | XXX |
| Rule of 40 | 28% | XXX | 30% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 33% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 16% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 10% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 32% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Kelun acquired XXX companies to date.
Last acquisition by Kelun was XXXXXXXX, XXXXX XXXXX XXXXXX . Kelun acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Kelun founded? | Kelun was founded in 2002. |
| Where is Kelun headquartered? | Kelun is headquartered in China. |
| Is Kelun publicy listed? | Yes, Kelun is a public company listed on SHE. |
| What is the stock symbol of Kelun? | Kelun trades under 002422 ticker. |
| When did Kelun go public? | Kelun went public in 2010. |
| Who are competitors of Kelun? | Similar companies to Kelun include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Kelun? | Kelun's current market cap is $8.6B |
| What is the current revenue of Kelun? | Kelun's last 12 months revenue is $3.0B. |
| What is the current revenue growth of Kelun? | Kelun revenue growth (NTM/LTM) is 4%. |
| What is the current EV/Revenue multiple of Kelun? | Current revenue multiple of Kelun is 2.7x. |
| Is Kelun profitable? | Yes, Kelun is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Kelun? | Kelun's last 12 months EBITDA is $704M. |
| What is Kelun's EBITDA margin? | Kelun's last 12 months EBITDA margin is 23%. |
| What is the current EV/EBITDA multiple of Kelun? | Current EBITDA multiple of Kelun is 11.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
